Nature Communications (Mar 2022)

Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma

  • Lorey K. Smith,
  • Tiffany Parmenter,
  • Margarete Kleinschmidt,
  • Eric P. Kusnadi,
  • Jian Kang,
  • Claire A. Martin,
  • Peter Lau,
  • Riyaben Patel,
  • Julie Lorent,
  • David Papadopoli,
  • Anna Trigos,
  • Teresa Ward,
  • Aparna D. Rao,
  • Emily J. Lelliott,
  • Karen E. Sheppard,
  • David Goode,
  • Rodney J. Hicks,
  • Tony Tiganis,
  • Kaylene J. Simpson,
  • Ola Larsson,
  • Benjamin Blythe,
  • Carleen Cullinane,
  • Vihandha O. Wickramasinghe,
  • Richard B. Pearson,
  • Grant A. McArthur

DOI
https://doi.org/10.1038/s41467-022-28705-x
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 21

Abstract

Read online

Different adaptive mechanisms have been reported to reduce the efficacy of mutant BRAF inhibition in melanoma. Here, the authors show BRAF inhibition induces the translational regulation of metabolic genes leading to acquired therapy resistance.